Owlet debuts new Dream Sock at Kind + Jugend 2024 and shares that the device will soon be available to even more parents across the globe.
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies.
Edwards Lifesciences announced the results from the RHEIA Trial.
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.
Transformative Angioplasty Sheath Platform Compatible with a Broad Range of Off-the-Shelf PTA and PTCA Angioplasty Balloons Cleared by FDA
Renew Biotechnologies is a dynamic holding company dedicated to acquiring, developing, and commercializing impactful biotechnology.
State legislators got a first hand look at Utah’s life sciences industry.
Temporary vessel occlusion a growing practice for trauma patients.
SINTX Technologies announced that its Board of Directors has initiated a process to explore potential strategic options for the Company.
Groundbreaking at-home pivotal trial of a much-anticipated therapeutic device is underway
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market